Clinical Trial Update: Biosimilar Retacrit® in the Treatment of Chemotherapy-induced Anaemia in Oncology and Haematology

View source ↗

Summary

This clinical trial update notes the completed study of the biosimilar epoetin alfa, Retacrit, for chemotherapy-induced anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Anemia

Drugs mentioned

• RETACRIT (EPOETIN ALFA-EPBX)

Snippet

Sponsor: Hospira, now a wholly owned subsidiary of Pfizer | Conditions: Chemotherapy-induced Anemia | Status: COMPLETED